| pubmed-article:8468392 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8468392 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:8468392 | lifeskim:mentions | umls-concept:C0038720 | lld:lifeskim |
| pubmed-article:8468392 | lifeskim:mentions | umls-concept:C0204727 | lld:lifeskim |
| pubmed-article:8468392 | lifeskim:mentions | umls-concept:C0205409 | lld:lifeskim |
| pubmed-article:8468392 | lifeskim:mentions | umls-concept:C0301869 | lld:lifeskim |
| pubmed-article:8468392 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8468392 | pubmed:dateCreated | 1993-5-7 | lld:pubmed |
| pubmed-article:8468392 | pubmed:abstractText | Selective extraction of sulfate conjugates of basic drugs from biological matrices has been difficult because of their highly polar nature. Immunoaffinity isolation may be the best solution to this analytical problem. This was tested for a model compound, the metabolite 4'-hydroxypropranolol sulfate (HOPS), which was effectively extracted from plasma by a column containing antibodies to the parent drug propranolol. The specificity was very high, giving little interference from the biological material in subsequent high-performance liquid chromatographic analysis with fluorometric detection. The method for HOPS was highly reproducible and provided a sensitivity of 1 ng/ml plasma. The technique was applied to measurements of HOPS in plasma after therapeutic doses of propranolol as well as to the individual enantiomers after chiral derivatization. | lld:pubmed |
| pubmed-article:8468392 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8468392 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8468392 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8468392 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8468392 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8468392 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8468392 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8468392 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8468392 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8468392 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8468392 | pubmed:issn | 0021-9673 | lld:pubmed |
| pubmed-article:8468392 | pubmed:author | pubmed-author:WalleTT | lld:pubmed |
| pubmed-article:8468392 | pubmed:author | pubmed-author:WalleU KUK | lld:pubmed |
| pubmed-article:8468392 | pubmed:author | pubmed-author:EllerT DTD | lld:pubmed |
| pubmed-article:8468392 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8468392 | pubmed:day | 26 | lld:pubmed |
| pubmed-article:8468392 | pubmed:volume | 612 | lld:pubmed |
| pubmed-article:8468392 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8468392 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8468392 | pubmed:pagination | 320-5 | lld:pubmed |
| pubmed-article:8468392 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8468392 | pubmed:meshHeading | pubmed-meshheading:8468392-... | lld:pubmed |
| pubmed-article:8468392 | pubmed:meshHeading | pubmed-meshheading:8468392-... | lld:pubmed |
| pubmed-article:8468392 | pubmed:meshHeading | pubmed-meshheading:8468392-... | lld:pubmed |
| pubmed-article:8468392 | pubmed:meshHeading | pubmed-meshheading:8468392-... | lld:pubmed |
| pubmed-article:8468392 | pubmed:meshHeading | pubmed-meshheading:8468392-... | lld:pubmed |
| pubmed-article:8468392 | pubmed:meshHeading | pubmed-meshheading:8468392-... | lld:pubmed |
| pubmed-article:8468392 | pubmed:meshHeading | pubmed-meshheading:8468392-... | lld:pubmed |
| pubmed-article:8468392 | pubmed:meshHeading | pubmed-meshheading:8468392-... | lld:pubmed |
| pubmed-article:8468392 | pubmed:meshHeading | pubmed-meshheading:8468392-... | lld:pubmed |
| pubmed-article:8468392 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8468392 | pubmed:articleTitle | Immunoaffinity isolation of the sulfate conjugate of 4'-hydroxypropranolol from plasma. | lld:pubmed |
| pubmed-article:8468392 | pubmed:affiliation | Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston 29425. | lld:pubmed |
| pubmed-article:8468392 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8468392 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
